Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor useLauren Veltri, Abraham S. Kanate, Aaron Cumpston et al.|Cytotherapy|2015Cited by 33
Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell TransplantationSherri Rauenzahn, Abraham S. Kanate, Quoc Truong et al.|Transplantation and Cellular Therapy|2013Cited by 18
Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantationAbraham S. Kanate, Mehdi Hamadani, Michael Craig et al.|Hematology/Oncology and Stem Cell Therapy|2011Cited by 10
Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) MobilizationLauren Veltri, Abraham S. Kanate, Alexandra Shillingburg et al.|Blood|2014Cited by 2
Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.Abraham S. Kanate, Michael Craig, Farhad Khimani et al.|Blood|2009Cited by 0